Alerts will be sent to your verified email
Verify EmailABBOTINDIA
Abbott India
|
Aurobindo Pharma
|
Alkem Laboratories
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
8.2 % | n/a | 73.0 % |
R&D as a % of Total Sales
|
0.02 % | 5.05 % | 5.0 % |
Financials
|
|||
5 yr Average ROE
|
30.11 % | 13.97 % | 17.38 % |
5yr average Equity Multiplier
|
1.43 | 1.51 | 1.39 |
5yr Average Asset Turnover Ratio
|
1.14 | 0.71 | 0.86 |
5yr Avg Net Profit Margin
|
18.53 % | 12.77 % | 14.54 % |
Price to Book
|
16.9 | 1.92 | 4.88 |
P/E
|
50.59 | 17.99 | 27.03 |
5yr Avg Cash Conversion Cycle
|
-46.68 Days | -49.62 Days | -61.46 Days |
Inventory Days
|
45.22 Days | 59.48 Days | 56.11 Days |
Days Receivable
|
19.34 Days | 28.34 Days | 44.62 Days |
Days Payable
|
109.21 Days | 115.71 Days | 122.42 Days |
5yr Average Interest Coverage Ratio
|
97.37 | 43.78 | 24.48 |
5yr Avg ROCE
|
38.77 % | 16.69 % | 22.76 % |
5yr Avg Operating Profit Margin
|
23.42 % | 19.28 % | 18.44 % |
5 yr average Debt to Equity
|
0.0 | 0.21 | 0.18 |
5yr CAGR Net Profit
|
15.41 % | 2.21 % | 6.44 % |
5yr Average Return on Assets
|
21.03 % | 9.18 % | 12.47 % |
Shareholdings
|
|||
Promoter Holding
|
74.99 % | 51.82 % | 53.04 % |
Share Pledged by Promoters
|
0.0 | 17.08 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.01 % | -4.1 % |
Change in Mutual Fund Holding (3 Yrs)
|
2.93 % | 9.14 % | 8.82 % |
Abbott India
|
Aurobindo Pharma
|
Alkem Laboratories
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|
Brand Wise Break-Up
|
Brand Wise Break-Up
|
-
|
-
|